0.09 | 7.44%
| Price and Volume | |
|---|---|
| Recent Price | 1.30 |
| 52 Week High | 5.34 |
| 52 Week Low | 1.15 |
| Avg. Daily Vol. (Mil) | 0.19 |
| Beta (3 year) | 1.08 |
| Share Related Items | |
| Mkt Cap (Mil) | 46.41 |
| Shares Out (Mil) | 35.70 |
| Float (Mil) | 32.30 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.70 |
| Current Ratio | 2.80 |
| LT Debt/ Equity | 0.03 |
| Total Debt / Equity | 0.04 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 6.40 |
| Price/Book | 9.37 |
| Price/Cash Flow | -13.80 |
| Per Share Data | |
| Earnings | -0.14 |
| Sales | 0.20 |
| Book Value | 0.14 |
| Cash Flow | -0.09 |
| Business Summary | |
|---|---|
| Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from radiation and other stresses. | |
| General Information | |
| 73 High Street Buffalo
Buffalo, NY 14203 |
|
| www.cbiolabs.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 58 | |
| CEO: Dr. Yakov Kogan,PhD | |
| Short Interest | |
| Current Month (Mil) | 3.00 |
| Previous Month (Mil) | 2.74 |
| Short Interest Ratio (Days) | 17.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -14.70 |
| Return on Investments | -76.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -81.20 |
| Profit Margin | -53.80 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet